FDA Vaccine Meeting
The upcoming FDA advisory panel meeting will provide a platform for the agency and Pfizer to present their analyses of clinical trial data involving 44,000 participants. Briefing documents will be released just two days prior, offering the public insight into the FDA's perspective and potential concerns. A vote at the end of the meeting will indicate whether the panel supports the vaccine's authorization.In this clip
From this podcast
Prognosis: Misconception
A Turning Point Week Ahead
Related Questions